SCHEMBL286913

SCHEMBL286913

O=C1CC2(CC2)CC(=O)O1

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
LMNA P02545 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL194872 0.88 TSHR (0.38) TSHR
SCHEMBL2761366 0.88 TSHR (0.38) TSHR
SCHEMBL2915774 0.87 TSHR (0.47) TSHRLMNA
SCHEMBL7338345 0.86 TSHR (0.36) TSHR
SCHEMBL11626081 0.86 TSHR (0.36) TSHR
SCHEMBL395804 0.86 TSHR (0.36) TSHR
SCHEMBL6944961 0.82 KDM4E (0.30) LMNA
SCHEMBL6946347 0.78
SCHEMBL13593718 0.78 ESR2 (0.34) TSHR
SCHEMBL13496495 0.75 TSHR (0.36) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2880008-A1 PROCESS FOR PREPARING SPIRO[2.5]OCTANE-5,7-DIONE Boehringer Ingelheim International GmbH (DE) 2015-06-10 EP claimed
US-20140336405-A1 Process for preparing spiro[2.5]octane-5,7-dione BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-13 US claimed
US-20140039203-A1 Process for preparing spiro[2.5]octane-5,7-dione BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-06 US claimed
WO-2014020038-A1 PROCESS FOR PREPARING SPIRO[2.5]OCTANE-5,7-DIONE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-06 WO claimed
EP-4719369-A2 INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING Celloram, Inc. (US) 2026-04-08 EP disclosed
WO-2025080689-A1 LIPID PRODRUGS OF BROMOLYSERGIDE AND USES THEREOF SEAPORT THERAPEUTICS, INC. (US) 2025-04-17 WO disclosed
WO-2024254161-A2 INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING CELLORAM INC. (US) 2024-12-12 WO disclosed
US-10570116-B2 1,4-dicarbonyl-piperidyl derivatives MERCK PATENT GMBH (DE) 2020-02-25 US disclosed
EP-3371166-B1 1,4-DICARBONYL-PIPERIDYL DERIVATIVES MERCK PATENT GMBH (DE) 2019-11-20 EP disclosed
EP-2880008-B1 PROCESS FOR PREPARING SPIRO[2.5]OCTANE-5,7-DIONE BOEHRINGER INGELHEIM INT (DE) 2019-05-29 EP disclosed
EP-2880008-B1 PROCESS FOR PREPARING SPIRO[2.5]OCTANE-5,7-DIONE BOEHRINGER INGELHEIM INT (DE) 2019-05-29 EP disclosed
US-20190092751-A1 1,4-DICARBONYL-PIPERIDYL DERIVATIVES MERCK PATENT GMBH (DE) 2019-03-28 US disclosed
US-20140039203-A1 Process for preparing spiro[2.5]octane-5,7-dione BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-06 US disclosed
WO-2014020038-A1 PROCESS FOR PREPARING SPIRO[2.5]OCTANE-5,7-DIONE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-06 WO disclosed
WO-2013116682-A1 MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 ENSEMBLE THERAPEUTICS CORPORATION (US) 2013-08-08 WO disclosed
US-20120122942-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS FLORIDA INSTITUTE OF TECHNOLOGY 2012-05-17 US disclosed
EP-2427430-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS The Royal Institution for the Advancement of Learning / McGill University (CA) 2012-03-14 EP disclosed
WO-2010127452-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2010-11-11 WO disclosed
US-5128359-A Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation LABORATOIRES UPSA (FR) 1992-07-07 US disclosed
US-5124336-A Cardiovascular disorders LABORATOIRES UPSA (FR) 1992-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140039203-A1 Process for preparing spiro[2.5]octane-5,7-dione SQLE, DHPS, CYP3A5 TSHR 2945/4885LMNA 928/4885CYP2C9 128/4885
US-10570116-B2 1,4-dicarbonyl-piperidyl derivatives TNKS, TANK, TBKBP1 TSHR 3489/4885LMNA 2999/4885CYP2C9 3606/4885
US-20120122942-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS OXER1, PTGIR, EDNRA TSHR 739/4885LMNA 3814/4885CYP2C9 696/4885
US-20190092751-A1 1,4-DICARBONYL-PIPERIDYL DERIVATIVES TNKS, TANK, TBKBP1 TSHR 3489/4885LMNA 2999/4885CYP2C9 3606/4885
US-20140336405-A1 Process for preparing spiro[2.5]octane-5,7-dione SQLE, DHPS, CYP3A5 TSHR 2945/4885LMNA 928/4885CYP2C9 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.